Skip to main content
Juan Varela, MD, Hematology, Orlando, FL

JuanCarlosVarelaMDPhD

Hematology Orlando, FL

Hematologic Oncology

Physician

Dr. Varela is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Varela's full profile

Already have an account?

  • Office

    1400 S Orange Ave
    Orlando, FL 32806
    Phone+1 321-841-2810
    Fax+1 321-843-6330

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2010 - 2013
  • Medical University of South Carolina
    Medical University of South CarolinaClass of 2010

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2017 - 2026
  • MA State Medical License
    MA State Medical License 2022 - 2024
  • SC State Medical License
    SC State Medical License 2015 - 2019
  • MD State Medical License
    MD State Medical License 2012 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Publications & Presentations

PubMed

Journal Articles

  • Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination Therapy  
    Shahram Mori, Juan Varela, Steven C Goldstein, Daniel O Persky, Clinical Lymphoma, Myeloma, & Leukemia

Abstracts/Posters

  • Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
    Juan Carlos Varela, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Authored Content

  • Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination TherapyNovember 2018

Press Mentions

  • AdventHealth Launches First-of-Its-Kind Immunotherapy Treatment, Clinical Trial for Specific Blood Cancer Patients
    AdventHealth Launches First-of-Its-Kind Immunotherapy Treatment, Clinical Trial for Specific Blood Cancer PatientsJune 12th, 2020
  • Contigo Fund Gets $150,000 Grant from Gilead
    Contigo Fund Gets $150,000 Grant from GileadOctober 17th, 2019
  • Vital £50,000 Boost for Dementia Research at St Andrews University
    Vital £50,000 Boost for Dementia Research at St Andrews UniversitySeptember 30th, 2019
  • Join now to see all